Skip to main content
Top
Gepubliceerd in: Quality of Life Research 9/2015

01-09-2015

Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate’s egg

Auteurs: Eamonn O’Leary, Frances J. Drummond, Anna Gavin, Heather Kinnear, Linda Sharp

Gepubliceerd in: Quality of Life Research | Uitgave 9/2015

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

The EORTC QLQ-PR25 was primarily developed to measure disease-specific health-related quality of life (HRQoL) of prostate cancer (PCa) patients undergoing active treatment. The growing number of cancer survivors has focussed interest on assessing survivors’ HRQoL. We evaluated psychometric properties of the EORTC QLQ-PR25 questionnaire amongst PCa survivors.

Methods

A postal questionnaire, including the QLQ-PR25, was administered to 6559 PCa survivors 2–18 years post-diagnosis, identified through population-based cancer registries in Ireland; 3348 participated. The QLQ-PR25 has been suggested to have five multi-item subscales measuring urinary (US), bowel (BS) and hormone treatment-related symptoms (TS), sexual activity (SA) and sexual functioning (SF), and a single item measuring bother due to using incontinence aids (IA). Reliability analysis, divergent validity, discriminant validity (compared to EORTC QLQ-C30, DASS-21 and EuroQoL EQ-5D-5L), and exploratory and confirmatory factor analysis (EFA, CFA) were undertaken.

Results

The percentage of survivors completing QLQ-PR25 subscales was: US-79 %; IA-20 %; BS-83 %; TS-86 %; SA-87 %; and SF-26 %. Reliability was acceptable (Cronbach’s α > 0.7) for three subscales (US, SA, SF). The instrument discriminated well between clinically distinct groups, especially those defined by primary treatment(s) and stage at diagnosis. The SA and SF subscales showed good discriminant validity compared to QLQ-C30, DASS-21 and EQ-5D-5L; other subscales did not. EFA reproduced a near fit to the proposed factor structure. CFA confirmed this.

Conclusion

This is the largest ever QLQ-PR25 validation study. When used in PCa survivors, although the proposed factor structure was confirmed, some of the subscales (e.g. BS and TS) showed poor reliability, a lack of discriminant validity and moderate levels of item non-response.
Literatuur
2.
go back to reference Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology, Biomarkers and Prevention, 19(8), 1893–1907.PubMedCrossRef Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology, Biomarkers and Prevention, 19(8), 1893–1907.PubMedCrossRef
3.
go back to reference De Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., et al. (2014). Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE-5—a population-based study. The lancet Oncology, 15(1), 23–34.PubMedCrossRef De Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., et al. (2014). Cancer survival in Europe 1999–2007 by country and age: Results of EUROCARE-5—a population-based study. The lancet Oncology, 15(1), 23–34.PubMedCrossRef
4.
go back to reference Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012). Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians, 62(4), 220–241. Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012). Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians, 62(4), 220–241.
5.
go back to reference Sharp, L., Deady, S., Gallagher, P., Molcho, M., Pearce, A., Thomas, A. A., Timmons, A., & Comber, H. (2014). The magnitude and characteristics of the population of cancer survivors: Using population-based estimates of cancer prevalence to inform service planning for survivorship care. BMC Cancer, 14(1), 767. Sharp, L., Deady, S., Gallagher, P., Molcho, M., Pearce, A., Thomas, A. A., Timmons, A., & Comber, H. (2014). The magnitude and characteristics of the population of cancer survivors: Using population-based estimates of cancer prevalence to inform service planning for survivorship care. BMC Cancer, 14(1), 767.
6.
go back to reference Bray, F., Ren, J.-S., Masuyer, E., & Ferlay, J. (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer, 132(5), 1133–1145.CrossRef Bray, F., Ren, J.-S., Masuyer, E., & Ferlay, J. (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer, 132(5), 1133–1145.CrossRef
7.
go back to reference Rnic, K., Linden, W., Tudor, I., Pullmer, R., & Vodermaier, A. (2013). Measuring symptoms in localized prostate cancer: A systematic review of assessment instruments. Prostate Cancer and Prostatic Diseases, 16(2), 111–122.PubMed Rnic, K., Linden, W., Tudor, I., Pullmer, R., & Vodermaier, A. (2013). Measuring symptoms in localized prostate cancer: A systematic review of assessment instruments. Prostate Cancer and Prostatic Diseases, 16(2), 111–122.PubMed
8.
go back to reference Van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S., et al. (2008). An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 44(16), 2418–2424.PubMedCrossRef Van Andel, G., Bottomley, A., Fosså, S. D., Efficace, F., Coens, C., Guerif, S., et al. (2008). An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. European Journal of Cancer, 44(16), 2418–2424.PubMedCrossRef
9.
go back to reference Arraras, J. I., Villafranca, E., Arias de la Vega, F., Romero, P., Rico, M., Vila, M., et al. (2009). The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients. Clinical and Translational Oncology, 11(3), 160–164.PubMedCrossRef Arraras, J. I., Villafranca, E., Arias de la Vega, F., Romero, P., Rico, M., Vila, M., et al. (2009). The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients. Clinical and Translational Oncology, 11(3), 160–164.PubMedCrossRef
10.
go back to reference Chie, W.-C., Yu, C.-C., & Yu, H.-J. (2010). Reliability and validity of the Taiwan Chinese version of the EORTC QLQ-PR25 in assessing quality of life of prostate cancer patients. Urological Science, 21(3), 118–125.CrossRef Chie, W.-C., Yu, C.-C., & Yu, H.-J. (2010). Reliability and validity of the Taiwan Chinese version of the EORTC QLQ-PR25 in assessing quality of life of prostate cancer patients. Urological Science, 21(3), 118–125.CrossRef
11.
go back to reference Chang, Y.-J., Liang, W.-M., Wu, H.-C., Lin, H.-C., Wang, J.-Y., Li, T.-C., et al. (2012). Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients. Health and Quality of Life Outcomes, 10(1), 96.PubMedCentralPubMedCrossRef Chang, Y.-J., Liang, W.-M., Wu, H.-C., Lin, H.-C., Wang, J.-Y., Li, T.-C., et al. (2012). Psychometric evaluation of the Taiwan Chinese version of the EORTC QLQ-PR25 for HRQOL assessment in prostate cancer patients. Health and Quality of Life Outcomes, 10(1), 96.PubMedCentralPubMedCrossRef
12.
go back to reference Park, J., Shin, D. W., Yun, S. J., Park, S.-W., Jeon, S. S., Kwak, C., et al. (2013). Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with prostate cancer-EORTC QLQ-PR25. Oncology, 85(5), 299–305.PubMedCrossRef Park, J., Shin, D. W., Yun, S. J., Park, S.-W., Jeon, S. S., Kwak, C., et al. (2013). Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with prostate cancer-EORTC QLQ-PR25. Oncology, 85(5), 299–305.PubMedCrossRef
13.
go back to reference Denham, J. W., Wilcox, C., Lamb, D. S., Spry, N. A., Duchesne, G., Atkinson, C., et al. (2012). Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiotherapy and Oncology, 105(2), 184–192.PubMedCrossRef Denham, J. W., Wilcox, C., Lamb, D. S., Spry, N. A., Duchesne, G., Atkinson, C., et al. (2012). Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. Radiotherapy and Oncology, 105(2), 184–192.PubMedCrossRef
14.
go back to reference Drummond, F.J., Kinnear, H., O’Leary, E., Donnelly, Gavin, A., & Sharp, L. (2015). Long-term health related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. Journal of Cancer Survivorship: Research and Practice. doi:10.1007/s11764-014-0419-6. Drummond, F.J., Kinnear, H., O’Leary, E., Donnelly, Gavin, A., & Sharp, L. (2015). Long-term health related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. Journal of Cancer Survivorship: Research and Practice. doi:10.​1007/​s11764-014-0419-6.
15.
go back to reference Selli, C., Bjartell, A., Burgos, J., Somerville, M., Palacios, J.-M., Benjamin, L., et al. (2014). Burden of illness in prostate cancer patients with a low-to-moderate risk of progression: A one-year, pan-European observational study. Prostate Cancer, 2014, 1–8.CrossRef Selli, C., Bjartell, A., Burgos, J., Somerville, M., Palacios, J.-M., Benjamin, L., et al. (2014). Burden of illness in prostate cancer patients with a low-to-moderate risk of progression: A one-year, pan-European observational study. Prostate Cancer, 2014, 1–8.CrossRef
17.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.PubMedCrossRef Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.PubMedCrossRef
18.
go back to reference Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the depression anxiety stress scales (2nd ed.). Sydney: Psychology Foundation. Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the depression anxiety stress scales (2nd ed.). Sydney: Psychology Foundation.
19.
go back to reference EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
20.
go back to reference Oemar, M., & Janssen, B. (2013). EQ-5D-5L user guide. Rotterdam: EuroQoL Group. Oemar, M., & Janssen, B. (2013). EQ-5D-5L user guide. Rotterdam: EuroQoL Group.
22.
go back to reference Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill. Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill.
23.
go back to reference De Camargo Cancela, M., Comber, H., & Sharp, L. (2013). Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: A population-based study. British Journal of Cancer, 109(1), 272–279.PubMedCentralPubMedCrossRef De Camargo Cancela, M., Comber, H., & Sharp, L. (2013). Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: A population-based study. British Journal of Cancer, 109(1), 272–279.PubMedCentralPubMedCrossRef
24.
go back to reference Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., et al. (2014). EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent—update 2013. European Urology, 65(1), 124–137.PubMedCrossRef Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., et al. (2014). EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent—update 2013. European Urology, 65(1), 124–137.PubMedCrossRef
25.
go back to reference Wilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., & Kane, R. L. (2008). Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Annals of Internal Medicine, 148(6), 435–448.PubMedCrossRef Wilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., & Kane, R. L. (2008). Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Annals of Internal Medicine, 148(6), 435–448.PubMedCrossRef
26.
go back to reference Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling: A Multidisciplinary Journal, 6(1), 1–55.CrossRef Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling: A Multidisciplinary Journal, 6(1), 1–55.CrossRef
27.
go back to reference Thomas, A. A., Timmons, A., Molcho, M., Pearce, A., Gallagher, P., Butow, P., et al. (2014). Quality of life in urban and rural settings: A study of head and neck cancer survivors. Oral Oncology, 50(7), 676–682.PubMedCrossRef Thomas, A. A., Timmons, A., Molcho, M., Pearce, A., Gallagher, P., Butow, P., et al. (2014). Quality of life in urban and rural settings: A study of head and neck cancer survivors. Oral Oncology, 50(7), 676–682.PubMedCrossRef
28.
go back to reference Glaser, A. W., Fraser, L. K., Corner, J., Feltbower, R., Morris, E. J. A., Hartwell, G., et al. (2013). Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: A cross-sectional survey. BMJ Open, 3(4), E002317. Glaser, A. W., Fraser, L. K., Corner, J., Feltbower, R., Morris, E. J. A., Hartwell, G., et al. (2013). Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: A cross-sectional survey. BMJ Open, 3(4), E002317.
Metagegevens
Titel
Psychometric evaluation of the EORTC QLQ-PR25 questionnaire in assessing health-related quality of life in prostate cancer survivors: a curate’s egg
Auteurs
Eamonn O’Leary
Frances J. Drummond
Anna Gavin
Heather Kinnear
Linda Sharp
Publicatiedatum
01-09-2015
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2015
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-0958-y

Andere artikelen Uitgave 9/2015

Quality of Life Research 9/2015 Naar de uitgave